Pyoderma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: PYD002 MIFTS: 49	Pyoderma Categories: Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Pyoderma

MalaCards integrated aliases for Pyoderma:

Name: Pyoderma ¹² ⁵⁴ ⁴⁴ ¹⁵ ⁷⁰ ³²

Classifications:

MalaCards categories:
Anatomical: Skin diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Diseases of the skin and subcutaneous tissue

Infections of the skin and subcutaneous tissue

Other local infections of skin and subcutaneous tissue

Pyoderma

External Ids:

Disease Ontology ¹² DOID:4223

ICD9CM ³⁴ 686.0

MeSH ⁴⁴ D011711

SNOMED-CT ⁶⁷ 267838007

ICD10 ³² L08.0

UMLS ⁷⁰ C0034212

Sources

Summaries for Pyoderma

Disease Ontology : ¹² A dermatitis that is characterized by a pyogenic infection causing the formation of pus.

MalaCards based summary : Pyoderma is related to pyogenic sterile arthritis, pyoderma gangrenosum, and acne and impetigo, and has symptoms including pruritus, exanthema and pustular rash. An important gene associated with Pyoderma is PSTPIP1 (Proline-Serine-Threonine Phosphatase Interacting Protein 1), and among its related pathways/superpathways are Integrin Pathway and Cytokine Signaling in Immune system. The drugs Adalimumab and Antirheumatic Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, neutrophil and myeloid, and related phenotypes are immune system and integument

Sources

Related Diseases for Pyoderma

Diseases related to Pyoderma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 795)

#	Related Disease	Score	Top Affiliating Genes
1	pyogenic sterile arthritis, pyoderma gangrenosum, and acne	33.0	SIGLEC5 PSTPIP1 MEFV
2	impetigo	31.6	MYOM2 DSG1 CCR6
3	ulcerative colitis	31.3	TNF NOD2 IL1R1 CXCL8 CCR6
4	colitis	31.3	TNF NOD2 IL1R1 CXCL8 CCR6
5	hidradenitis	31.2	TNF NOD2 MEFV
6	acne	31.2	TNF PSTPIP1 ITGB2 IFNA2 CXCL8
7	vasculitis	31.1	TNF MEFV ITGB2 IFNA2 APOH
8	crohn's disease	31.1	TNF NOD2 MEFV CXCL8 CCR6
9	hidradenitis suppurativa	31.1	TNF NOD2 MEFV
10	erythema nodosum	31.0	TNF NOD2 CXCL8
11	pyoderma gangrenosum	30.8	TNF SIGLEC5 PSTPIP1 NOD2 MMP9 MMP26
12	crohn's colitis	30.8	TNF NOD2 CXCL8 CCR6
13	fasciitis	30.8	TNF MYOM2 MMP1 CXCL8
14	chronic recurrent multifocal osteomyelitis	30.7	TNF PSTPIP1 MEFV
15	osteomyelitis	30.7	TNF NOD2 MEFV CXCL8 CSF3
16	panniculitis	30.7	TNF CSF3 BTK
17	myelofibrosis	30.7	TNF IFNA2 CXCL8 CSF3
18	scabies	30.7	CXCL8 CSF3 CCR6
19	erythema elevatum diutinum	30.6	PSTPIP1 CXCL8
20	skin disease	30.6	TNF SIGLEC5 MMP1 ITGB2 DSG1 CXCL8
21	pustulosis of palm and sole	30.6	TNF SIGLEC5 PSTPIP1 CXCL8 CCR6
22	pharyngitis	30.5	TNF MYOM2 MEFV CXCL8
23	purpura	30.5	TNF MEFV F3 APOH
24	diverticulitis	30.5	TNF MMP9 CCR6
25	pouchitis	30.5	TNF NOD2
26	scleritis	30.4	TNF MMP9 ITGB2 CCR6
27	antiphospholipid syndrome	30.4	TNF F3 APOH
28	psoriasis	30.4	TNF NOD2 ITGB2 IL1R1 CXCL8 CCR6
29	collagenous colitis	30.4	NOD2 MMP9 MMP1
30	keratitis, hereditary	30.4	TNF MMP9 CXCL8 CCR6
31	spondylitis	30.4	TNF NOD2 CCR6
32	erysipelas	30.4	TNF MYOM2 MEFV
33	sapho syndrome	30.4	SIGLEC5 NOD2 CXCL8
34	rosacea	30.4	TNF MMP9 CXCL8 CCR6
35	monoclonal gammopathy of uncertain significance	30.4	TNF MYOM2 CCR6
36	disease by infectious agent	30.4	TNF SIGLEC5 NOD2 CCR6
37	diarrhea	30.4	TNF NOD2 IFNA2 CXCL8 CSF3
38	leukocyte adhesion deficiency, type i	30.4	ITGB2 CXCL8 CSF3 CCR6
39	syphilis	30.3	TNF CCR6 APOH
40	cellulitis	30.3	TNF MYOM2 IL1R1 F3 CSF3 CCR6
41	dermatitis	30.3	TNF NOD2 DSG1 CXCL8 CCR6
42	cholangitis	30.3	TNF NOD2 F3 CXCL8
43	neutropenia	30.3	TNF IFNA2 CXCL8 CSF3 BTK
44	sclerosing cholangitis	30.3	TNF NOD2 CXCL8
45	fungal infectious disease	30.3	TNF CXCL8 CSF3 CCR6
46	spondyloarthropathy 1	30.3	TNF NOD2 IL1R1 CCR6
47	exanthem	30.3	TNF MEFV F3 CXCL8 CSF3 CCR6
48	brucellosis	30.3	TNF MEFV CXCL8
49	pericarditis	30.3	TNF MEFV CXCL8
50	cryoglobulinemia	30.3	TNF IFNA2 APOH

Comorbidity relations with Pyoderma via Phenotypic Disease Network (PDN):

Acute Cystitis	Decubitus Ulcer
Deficiency Anemia	Heart Disease
Peripheral Vascular Disease

Graphical network of the top 20 diseases related to Pyoderma:

Sources

Symptoms & Phenotypes for Pyoderma

UMLS symptoms related to Pyoderma:

pruritus; exanthema; pustular rash

MGI Mouse Phenotypes related to Pyoderma:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	immune system	MP:0005387	9.77	BTK CCR6 CSF3 F3 IL1R1 ITGB2
2	integument	MP:0010771	9.32	BTK CSF3 DSG1 F3 IL1R1 ITGB2

Sources

Drugs & Therapeutics for Pyoderma

Drugs for Pyoderma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 14)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Adalimumab

Approved, Experimental

Phase 3

331731-18-1

16219006

Synonyms:

331731-18-1

Adalimumab

Adalimumab (genetical recombination)

Adalimumab (genetical recombination) (JAN)

Adalimumab (USAN/INN)

adalimumab-adaz

adalimumab-adbm

adalimumab-afzb

adalimumab-atto

adalimumab-bwwd

adalimumab-fkjp

D02597

Humira

Humira (TN)

Humira Pen

Ig gamma-1 chain C region

Antirheumatic Agents

Phase 3

Anti-Inflammatory Agents

Phase 3

Pharmaceutical Solutions

Phase 3

Ixekizumab

Approved, Investigational

Phase 2

1143503-69-8

Dermatologic Agents

Phase 2

Antibodies

Phase 2

Immunoglobulins

Phase 2

Antibodies, Monoclonal

Phase 2

Immunologic Factors

Phase 2

Infliximab

Approved

170277-31-3

Tyrosine

Approved, Investigational, Nutraceutical

60-18-4

6057

Synonyms:

(-)-a-Amino-p-hydroxyhydrocinnamate

(-)-a-Amino-p-hydroxyhydrocinnamic acid

(-)-alpha-Amino-p-hydroxyhydrocinnamate

(-)-alpha-Amino-p-hydroxyhydrocinnamic acid

(-)-Α-amino-p-hydroxyhydrocinnamate

(−)-α-amino-p-hydroxyhydrocinnamic acid

(-)-Α-amino-p-hydroxyhydrocinnamic acid

(2S)-2-Amino-3-(4-hydroxyphenyl)propanoate

(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid

(2S)-2-Amino-3-(4-hydroxyphenyl)propanoic acid

(S)-(-)-Tyrosine

(S)-2-Amino-3-(4-hydroxyphenyl)propionic acid

(S)-2-Amino-3-(p-hydroxyphenyl)propionate

(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid

(S)-3-(p-Hydroxyphenyl)alanine

(S)-a-Amino-4-hydroxybenzenepropanoate

(S)-a-Amino-4-hydroxy-benzenepropanoate

(S)-a-Amino-4-hydroxybenzenepropanoic acid

(S)-a-Amino-4-hydroxy-benzenepropanoic acid

(S)-alpha-Amino-4-hydroxybenzenepropanoate

(S)-alpha-Amino-4-hydroxy-benzenepropanoate

(S)-alpha-amino-4-Hydroxybenzenepropanoic acid

(S)-alpha-Amino-4-hydroxybenzenepropanoic acid

(S)-alpha-Amino-4-hydroxy-benzenepropanoic acid

(S)-Tyrosine

(S)-Α-amino-4-hydroxybenzenepropanoate

(S)-α-amino-4-hydroxybenzenepropanoic acid

(S)-Α-amino-4-hydroxybenzenepropanoic acid

140-43-2

1991-85-1

25619-78-7

2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoate

2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoic acid

2-Amino-3-(p-hydroxyphenyl)propionic acid

2csm

3-(4-Hydroxyphenyl)-L-alanine

3-(p-Hydroxyphenyl)alanine

46209-14-7

4-hydroxy-L-phenylalanine

4-Hydroxy-L-phenylalanine

4ts1

55520-40-6

60-18-4

93829_FLUKA

93829_SIGMA

AB1002647

AC-11295

AC1L1LPI

AC1Q4U7L

AC1Q4U7M

AI3-09055

alpha-Amino-beta-(4-hydroxyphenyl)propionic acid

AR-1J3457

BB_NC-1194

Benzenepropanoate

Benzenepropanoic acid

beta-(p-Hydroxyphenyl)alanine

bmse000051

C00082

CHEBI:17895

CHEMBL925

CID6057

D00022

DB00135

DB03839

DD69927C-C6A8-4BC6-8E9A-0AB423B176E7

DTY

EINECS 200-460-4

FEMA No. 3736

Free-Form L-Tyrosine

HSDB 2003

H-Tyr-OH

L Tyrosine

L-(-)-Tyrosine

L-2-Amino-3-p-hydroxyphenylpropanoic acid

L-p-Tyrosine

LS-2336

L-Tyrosin

L-tyrosine

L-Tyrosine (9CI)

L-Tyrosine (JAN)

L-Tyrosine hydrochloride

L-Tyrosine, homopolymer

L-Tyrosine, monomer

Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs

Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide

Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide, <3 kd fraction

Melanin synthesized from Tyr substrate catalyzed by tyrosinase, brominated with N-bromosuccinimide

Melanin synthesized from Tyr substrate catalyzed by tyrosinase, sulfonated using sulfur trioxide/DMF complex for 1.5-7 hours

MolPort-001-792-016

NCGC00159350-02

NCGC00159350-03

nchembio.105-comp1

nchembio.121-comp7

nchembio.186-comp84

nchembio.284-comp7

nchembio816-comp11

NSC 82624

Para tyrosine

Para-tyrosine

p-Tyrosine

Rxosine

T0550

T3754_SIAL

T4321_SIAL

T4321_SIGMA

T8566_SIGMA

tirosina

Tirosina

Tirosina [Spanish]

tyr

Tyr

TYR NH3+ COOH

tyrosine

Tyrosine

TYROSINE

Tyrosine (USP/INN)

Tyrosine (VAN)

Tyrosine [USAN:INN]

Tyrosine Power

Tyrosine, L- (8CI)

Tyrosine, L isomer

Tyrosine, L-isomer

Tyrosinum

Tyrosinum [Latin]

UNII-42HK56048U

W373605_ALDRICH

Gastrointestinal Agents

Vaccines

Interventional clinical trials:

(show all 26)

#	Name	Status	NCT ID	Phase	Drugs
1	Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas	Withdrawn	NCT00202891	Phase 4	sisomicin
2	A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan	Completed	NCT03311464	Phase 3	adalimumab
3	A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum	Terminated	NCT02315417	Phase 3	gevokizumab;Placebo;gevokizumab open-label
4	A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma Gangrenosum	Terminated	NCT02318914	Phase 3	gevokizumab
5	A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum	Terminated	NCT02326740	Phase 3	gevokizumab;Placebo;gevokizumab open-label
6	An Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum	Completed	NCT01882504	Phase 2	gevokizumab
7	An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum	Completed	NCT03137160	Phase 2
8	A Phase II Multi Center Open Label Pilot Study To Assess a Potential Effect of an Anti-Il-1-Beta Antagonist in the Treatment of Pyoderma Gangrenosum	Completed	NCT01302795	Phase 2	Canakinumab
9	A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum	Completed	NCT01965613	Phase 2
10	Open Label Exploratory Phase 2a Trial to Investigate the Safety and Efficacy of IFX-1 in Treating Subjects With Pyoderma Gangrenosum (Optima)	Recruiting	NCT03971643	Phase 2	IFX-1
11	Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum	Active, not recruiting	NCT02733094	Phase 1, Phase 2	Secukinumab
12	The Efficacy and Safety of Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum	Not yet recruiting	NCT04274166	Phase 2	secukinumab 150 mg (2 injections per dose
13	A Phase 2a, Open-label, Proof of Concept Study to Determine the Efficacy and Safety of Etrasimod (APD334) in Patients With Pyoderma Gangrenosum	Terminated	NCT03072953	Phase 2	APD334
14	Multi Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum	Withdrawn	NCT00730717	Phase 2	Humira;Humira
15	A Multi-Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum (HUM 04-37)	Withdrawn	NCT00690846	Phase 2	adalimumab
16	Retrospective Multicenter Observational Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma Gangrenosum in Patients Diagnosed With This Pathology Between 2000 and 2015	Unknown status	NCT03636737
17	Assessment of the Enrichment of Rare Coding Genetic Variants in Patients Affected by Neutrophil-Mediated Inflammatory Dermatoses	Unknown status	NCT01952275
18	Tele-dermatology of Skin Cancer: a Randomized Trial Comparing Remote Assessment With Conventional Visits in a Cohort of Local Health Authority Employees in the Province of Bergamo (the Shoot the Mole Study)	Completed	NCT02902822
19	An Open Label Single Center Pilot Study Investigating the Clinical Response and Mechanism of Action of Infliximab in the Treatment of Adults With Inflammatory Bowel Disease Who Have Moderate to Severe Pyoderma Gangrenosum	Completed	NCT00791557		Infliximab
20	The Epidemiology of Group A Streptococcal Infections in Fiji (Fiji GrASP) Part 3: The Incidence of Group A Streptococcal Pharyngitis and the Prevalence of Pyoderma and Scabies in School Children in Fiji, and Establishing Immunologic Correlates of Protection for a J8 Vaccine	Completed	NCT00284882
21	The Epidemiology of Group A Streptococcal Infections in Fiji (Fiji GrASP) - Part 4 -The Prevalence of Group A Streptococcal Pyoderma and Scabies in Infants in Fiji	Completed	NCT00436891
22	The Epidemiology of Group A Streptococcal Infections in Fiji (Fiji GrASP) Part 1: The Prevalence of Rheumatic Heart Disease, Pyoderma and Scabies in School Children in Fiji	Completed	NCT00284843
23	East Arnhem Healthy Skin Project: A Regional Collaboration to Reduce Scabies, Skin Sores and Associated Chronic Diseases, Including Rheumatic Fever and Renal Disease, Among Australian Aboriginal Communities	Completed	NCT00884728
24	Post-marketing Observational Study for Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)	Recruiting	NCT04750213
25	A Real World, Observational Registry of Chronic Wounds and Ulcers to Assess Quality of Care, Evidence Based Practice and Outcomes Using Linked Electronic Health Record Data	Recruiting	NCT02280733
26	Expression of the JAK-STAT Signaling Pathway in Pyoderma Gangrenosum Pathological Biopsy	Not yet recruiting	NCT04792957

Search NIH Clinical Center for Pyoderma

Cochrane evidence based reviews: pyoderma

Sources

Genetic Tests for Pyoderma

Sources

Anatomical Context for Pyoderma

MalaCards organs/tissues related to Pyoderma:

⁴⁰

Skin, Neutrophil, Myeloid, Breast, Spleen, Colon, Thyroid

Sources

Publications for Pyoderma

Articles related to Pyoderma:

(show top 50) (show all 4757)

#	Title	Authors	PMID	Year
1	De novo mutation in the BTK gene of atypical X-linked agammaglobulinemia in a patient with recurrent pyoderma. ⁶¹ ⁵⁴	Lin MT...Yang HC	16729790	2006
2	Prediction of the therapeutic mechanism responsible for the effects of Sophora japonica flower buds on contact dermatitis by network-based pharmacological analysis. ⁶¹	Kim Y...An W	33493588	2021
3	Pyoderma gangrenosum solved by ustekinumab therapy. ⁶¹	Lopez Gonzalez J...Hernandez Martinez A	33069432	2021
4	Retraction notice to "Pyoderma gangrenosum in a cesarean section wound in a woman with myelodysplastic syndrome: A case report" [Case Reports in Women's Health 28 (2020) e00253]. ⁶¹	Suzuki N...Fujimori K	33614419	2021
5	[An unusually painful leg ulcer in an 81-year-old patient: an interdisciplinary challenge]. ⁶¹	Pfeifer J...Meletiadis K	33284357	2021
6	Dermatologic sequelae of breast cancer: From disease, surgery, and radiation. ⁶¹	Milam EC...Pomeranz MK	33226140	2021
7	Vulvovaginal pyoderma gangrenosum associated with rituximab use in 2 patients with rheumatoid arthritis. ⁶¹	Sotzen JR...Stratman EJ	33778138	2021
8	Various skin manifestations related to inflammatory bowel disease: A nationwide cross-sectional study on the Korean population. ⁶¹	Jo UH...Park H	33608949	2021
9	Newly isolated lytic bacteriophages for Staphylococcus intermedius, structurally and functionally stabilized in a hydroxyethylcellulose gel containing choline geranate: Potential for transdermal permeation in veterinary phage therapy. ⁶¹	Silva EC...Balcao VM	33440244	2021
10	The use of MATRIDERMⓇ as a single stage salvage procedure to cover exposed dura Mater. ⁶¹	Coulie J...Coyette M	33319011	2021
11	Demodectic mange in threatened southern sea otters (Enhydra lutris nereis). ⁶¹	Javeed N...Miller MA	33739551	2021
12	[Healing of severe morbus Crohn-related pyoderma gangrenosum after colectomy]. ⁶¹	Henneberg J...Munck LK	33734075	2021
13	Care and treatment of peristomal gangrenous pyoderma. A study of three cases. ⁶¹	Julve-Herraiz L...Garcia-Costa B	33541774	2021
14	Using item response theory (IRT) to improve the efficiency of the Simple Clinical Colitis Activity Index (SCCAI) for patients with ulcerative colitis. ⁶¹	Walsh A...Bauermeister S	33752610	2021
15	Estimating the Odds of Ulcerative Colitis-Associated Pyoderma Gangrenosum: A Population-Based Case-Control Study. ⁶¹	Kridin K...Cohen AD	33647909	2021
16	A case of myeloperoxidase-antineutrophil cytoplasmic antibody and anticardiolipin antibody-positive pyogenic arthritis, pyoderma gangrenosum, acne and hidradenitis suppurativa (PAPASH) syndrome with colitis. ⁶¹	Kawanishi K...Koiwa F	33560194	2021
17	Treatment of pyoderma gangrenosum: A multicenter survey-based study assessing satisfaction and quality of life. ⁶¹	Hobbs MM...Ortega-Loayza AG	33394563	2021
18	Pyoderma gangrenosum associated to the use of cocaine/levamisole. Series of three cases and literature review. ⁶¹	Martinez-Gomez M...Velasquez-Lopera MM	33640188	2021
19	Recalcitrant cutaneous pyoderma gangrenosum with pulmonary involvement resolved with treatment of underlying plasma cell dyscrasia. ⁶¹	Hooton TA...Olerud JE	33604440	2021
20	Successful treatment of pyoderma gangrenosum associated with IgA gammopathy with the IL-1 receptor antagonist anakinra. ⁶¹	Rousset P...Passeron T	33657262	2021
21	Pyoderma gangrenosum secondary to caesarean section treated with negative pressure wound therapy and skin graft. ⁶¹	Luo H...Lai W	33559207	2021
22	Pyoderma gangrenosum with plasma cell dyscrasia should be subject for anti-myeloma treatment. ⁶¹	Nahi H...Kuzmina N	33751551	2021
23	Pyoderma Gangrenosum: A Retrospective Study of Clinical Charac-teristics, Comorbidities, Response to Treatment and Mortality Related to Prednisone Dose. ⁶¹	Schosler L...Bech R	33686448	2021
24	First case of lenvatinib-induced pyoderma gangrenosum: Possible management with dose reduction. ⁶¹	Miyagawa A...Inazumi T	33651422	2021
25	Pyoderma gangrenosum associated with Takayasu's arteritis in a young Caucasian woman and response to biologic therapy with tocilizumab. ⁶¹	Choong DJ...Vinciullo C	33598515	2021
26	[Lung involvement of pyoderma gangrenosum: Diagnostic and therapeutic discussion based on a case report and a targeted literature review]. ⁶¹	Gallou S...Aouba A	33773848	2021
27	Mycophenolate mofetil as adjunctive therapy to corticosteroids for the treatment of pyoderma gangrenosum: a case series and literature review. ⁶¹	Hrin ML...Feldman SR	33739458	2021
28	The role of negative pressure wound therapy (NPWT) on the treatment of pyoderma gangrenosum: A systematic review and personal experience. ⁶¹	Almeida IR...Farina Junior JA	33772964	2021
29	Abdominal Pyoderma Gangrenosum, Harbinger of Takayasu Arteritis in an African American Patient. ⁶¹	Thibodeaux QG...Patel NJ	30044262	2021
30	Pyoderma gangrenosum associated with limited cutaneous systemic sclerosis: a rare case with literature review. ⁶¹	Skopis M...Bag-Ozbek A	32676919	2021
31	Efficacy and safety of skin grafting in treatment of vasculitic ulcer and pyoderma gangrenosum-A systematic review. ⁶¹	Morgenstjerne-Schwenck LET...Prasad SC	33377584	2021
32	Pyoderma gangrenosum with thymoma and myasthenia gravis: A case report. ⁶¹	Tuncez Akyurek F...Saylam Kurtipek G	32920928	2021
33	An unusual triple association: Superficial granulomatous pyoderma, subcorneal pustular dermatosis, IgA multiple myeloma. ⁶¹	Lamberti A...Rubegni P	33245568	2021
34	Pyoderma gangrenosum of the breast revealing contralateral breast carcinoma. ⁶¹	Calado R...Santiago L	33675057	2021
35	Recurrent necrotizing cellulitis, multi-organ autoimmune disease and humoral immunodeficiency due to a novel NFKB1 frameshift mutation. ⁶¹	Bergbreiter A...Schreml S	33486103	2021
36	Pyoderma Gangrenosum with an Underlying Leukocyte Adhesion Deficiency Type 1 (LAD-1) and Pregnancy in the Shade of COVID-19 Epidemic: A Patient and Physician Experience. ⁶¹	Opalinska A...Reich A	33686591	2021
37	Pyoderma gangrenosum and cobalamin deficiency in systemic lupus erythematosus: a rare but non fortuitous association. ⁶¹	Teoh SC...Teh CL	33653418	2021
38	Primary breast pyoderma gangrenosum: an uncommon cause of breast ulcer. ⁶¹	Duran-Martinez M...Briceno-Delgado J	33511730	2021
39	[Current dermatology guidelines in Germany and Europe : A selection of clinically relevant recommendations]. ⁶¹	Nast A...Gaskins M	33666670	2021
40	The Temporal Relationships and Associations between Cutaneous Manifestations and Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study. ⁶¹	Hung YT...Huang YH	33810197	2021
41	Extranodal NK/T cell lymphoma, nasal type, mimicking a bullous pyoderma gangrenosum. ⁶¹	Ma SH...Ho YH	33527364	2021
42	Cranial aseptic osteomyelitis associated with pyoderma gangrenosum. ⁶¹	Pique-Duran E...Espejo-Gil AM	33546980	2021
43	Superficial Granulomatous Pyoderma Gangrenosum Involving the Face: A Case Series of Five Patients and a Review of the Literature. ⁶¹	Shavit E...Alavi A	33541119	2021
44	An extensive pyoderma gangrenosum mimicking necrotizing fasciitis: An unusual case report. ⁶¹	Aziret M...Cevrioglu AS	33691271	2021
45	Pyoderma gangrenosum following an unplanned caesarean section: a patient revisited. ⁶¹	Ghumra W...Azurdia RM	33619133	2021
46	Pyoderma gangrenosum of the penis. ⁶¹	Loloi J...MacDonald SM	33625348	2021
47	One health approach to genetic relatedness in SCCmec between methicillin-resistant Staphylococcus isolates from companion dogs with pyoderma and their owners. ⁶¹	Kang JH...Hwang CY	33385887	2021
48	Guselkumab as a treatment option for recalcitrant pyoderma gangrenosum. ⁶¹	Baier C...Barak O	33490346	2021
49	Infliximab Prophylaxis in Patients With Postoperative Pyoderma Gangrenosum Requiring Surgical Intervention. ⁶¹	Dowd M...Gallitano S	31714378	2021
50	Pyoderma gangrenosum underrepresentation in non-dermatological literature. ⁶¹	Reese AM...Ortega-Loayza AG	31913849	2021

Sources

Genes for Pyoderma

Genes related to Pyoderma (0 elite genes):

(show all 26)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	PSTPIP1	Proline-Serine-Threonine Phosphatase Interacting Protein 1	Protein Coding	37.31	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Summaries Variants (show sections)
2	TNF	Tumor Necrosis Factor	Protein Coding	13.9	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	MEFV	MEFV Innate Immuity Regulator, Pyrin	Protein Coding	13.72	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	CSF3	Colony Stimulating Factor 3	Protein Coding	12.94	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	NOD2	Nucleotide Binding Oligomerization Domain Containing 2	Protein Coding	12.82	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	12.79	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	IL1R1	Interleukin 1 Receptor Type 1	Protein Coding	11.95	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	ITGB2	Integrin Subunit Beta 2	Protein Coding	11.2	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	MMP9	Matrix Metallopeptidase 9	Protein Coding	11.01	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	F3	Coagulation Factor III, Tissue Factor	Protein Coding	10.96	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	IFNA2	Interferon Alpha 2	Protein Coding	10.82	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	BTK	Bruton Tyrosine Kinase	Protein Coding	10.68	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	16729790
13	APOH	Apolipoprotein H	Protein Coding	10.1	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	MMP26	Matrix Metallopeptidase 26	Protein Coding	9.93	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	MMP1	Matrix Metallopeptidase 1	Protein Coding	9.8	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	MMP10	Matrix Metallopeptidase 10	Protein Coding	9.62	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	8.17	DISEASES inferred ¹⁵ ¹⁵
18	SIGLEC5	Sialic Acid Binding Ig Like Lectin 5	Protein Coding	8.1	DISEASES inferred ¹⁵ ¹⁵
19	MYOM2	Myomesin 2	Protein Coding	7.8	DISEASES inferred ¹⁵
20	DSG1	Desmoglein 1	Protein Coding	7.41	DISEASES inferred ¹⁵
21	EDNRB	Endothelin Receptor Type B	Protein Coding	7	DISEASES inferred ¹⁵
22	NLRP3	NLR Family Pyrin Domain Containing 3	Protein Coding	6.79	DISEASES inferred ¹⁵
23	IL1B	Interleukin 1 Beta	Protein Coding	6.71	DISEASES inferred ¹⁵
24	IL36RN	Interleukin 36 Receptor Antagonist	Protein Coding	6.67	DISEASES inferred ¹⁵
25	DSG3	Desmoglein 3	Protein Coding	6.63	DISEASES inferred ¹⁵
26	CRP	C-Reactive Protein	Protein Coding	6.6	DISEASES inferred ¹⁵

Sources

Variations for Pyoderma

Sources

Expression for Pyoderma

Search GEO for disease gene expression data for Pyoderma.

Sources

Pathways for Pyoderma

Pathways related to Pyoderma according to GeneCards Suite gene sharing:

(show all 25)

#	Super pathways	Score	Top Affiliating Genes
1	Integrin Pathway ⁶³ Show member pathways FAK1 Signaling ⁶³ GnRH Signaling ⁶³ Inhibition of Angiogenesis by TSP1 ⁶³ Transendothelial Migration of Leukocytes ⁶³ UPA-UPAR Pathway ⁶³	13.32	MMP9 MMP26 MMP10 MMP1 ITGB2 CXCL8
2	Cytokine Signaling in Immune system ⁶⁵ Show member pathways Signaling by Interleukins ⁶⁵	13.24	TNF NOD2 MMP9 MMP1 ITGB2 IL1R1
3	Innate Immune System ⁶⁵ Show member pathways Immune System ⁶⁵ Neutrophil degranulation ⁶⁵	13.09	TNF SIGLEC5 PSTPIP1 NOD2 MMP9 MMP1
4	Toll-Like receptor Signaling Pathways ⁶⁴ Show member pathways IL-1 Family Signaling Pathways ⁶⁴ Immune response IL-1 signaling pathway ²³ Immune response TLR3 and TLR4 induce TICAM1-specific signaling pathway ²³ Inflammasome Activation Pathways ⁶⁴ Mucin expression in CF via TLRs, EGFR signaling pathways ²³ NOD-like Receptor Signaling Pathways ⁶⁴	12.62	TNF NOD2 IL1R1 IFNA2 F3 CXCL8
5	IL-17 Family Signaling Pathways ⁶⁴ Show member pathways IL17 signaling pathway ¹ IL-17 signaling pathway ³⁶ Interleukin-17 signaling ⁶⁵ Mucin expression in CF via IL-6, IL-17 signaling pathways ²³	12.23	TNF MMP9 MMP1 CXCL8 CSF3
6	Tuberculosis ³⁶	12.15	TNF NOD2 ITGB2 IFNA2
7	Spinal Cord Injury ¹	11.94	TNF MMP9 IL1R1 CXCL8
8	NF-kappa B signaling pathway ³⁶	11.87	TNF IL1R1 CXCL8 BTK
9	Amoebiasis ³⁶	11.85	TNF ITGB2 IL1R1 CXCL8
10	Rheumatoid arthritis ³⁶	11.79	TNF MMP1 ITGB2 CXCL8
11	Interleukin-4 and 13 signaling ⁶⁵	11.71	TNF MMP9 MMP1 ITGB2 CXCL8
12	Innate Lymphoid Cell Differentiation Pathways ⁶⁴	11.7	TNF IL1R1 CCR6
13	NOD-like receptor signaling pathway ³⁶	11.69	TNF PSTPIP1 NOD2 MEFV IFNA2 CXCL8
14	Pertussis ³⁶	11.67	TNF ITGB2 CXCL8
15	Bladder cancer ³⁶ ¹	11.65	MMP9 MMP1 CXCL8
16	IgA-Producing B Cells in the Intestine ⁶⁴	11.6	TNF ITGB2 CCR6
17	Photodynamic therapy-induced NF-kB survival signaling ¹ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²³	11.56	TNF MMP9 MMP1 CXCL8
18	Matrix Metalloproteinases ¹ Show member pathways Activation of Matrix Metalloproteinases ⁶⁵ Inhibition of Matrix Metalloproteinases ⁶³	11.55	TNF MMP9 MMP26 MMP10 MMP1
19	Legionellosis ³⁶	11.53	TNF ITGB2 CXCL8
20	Lung fibrosis ¹	11.53	TNF MMP9 CXCL8 CSF3
21	Cell adhesion_ECM remodeling ²³	11.49	MMP9 MMP10 MMP1 CXCL8
22	amb2 Integrin signaling ¹	11.44	TNF MMP9 ITGB2
23	Malaria ³⁶	11.37	TNF ITGB2 CXCL8 CSF3
24	Interleukin-10 signaling ⁶⁵	11.31	TNF IL1R1 CXCL8 CSF3
25	Validated transcriptional targets of AP1 family members Fra1 and Fra2 ¹	11.27	MMP9 MMP1 CXCL8

Sources

GO Terms for Pyoderma

Cellular components related to Pyoderma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	9.7	TNF MMP9 MMP26 MMP10 MMP1 IL1R1
2	ficolin-1-rich granule membrane	GO:0101003	9.33	SIGLEC5 ITGB2 DSG1
3	cell surface	GO:0009986	9.17	TNF NOD2 ITGB2 IL1R1 F3 CCR6

Biological processes related to Pyoderma according to GeneCards Suite gene sharing:

(show all 17)

#	Name	GO ID	Score	Top Affiliating Genes
1	immune response	GO:0006955	9.95	TNF IL1R1 CXCL8 CSF3 CCR6
2	leukocyte migration	GO:0050900	9.83	TNF MMP9 MMP1 ITGB2
3	cellular response to lipopolysaccharide	GO:0071222	9.76	TNF NOD2 CXCL8 CSF3
4	calcium-mediated signaling	GO:0019722	9.74	CXCL8 CCR6 BTK
5	extracellular matrix disassembly	GO:0022617	9.71	MMP9 MMP10 MMP1
6	positive regulation of NF-kappaB transcription factor activity	GO:0051092	9.71	TNF NOD2 ITGB2 BTK
7	positive regulation of interleukin-8 production	GO:0032757	9.69	TNF NOD2 F3
8	humoral immune response	GO:0006959	9.67	TNF IFNA2 CCR6
9	defense response	GO:0006952	9.67	TNF NOD2 IFNA2 CXCL8
10	extracellular matrix organization	GO:0030198	9.63	TNF MMP9 MMP26 MMP10 MMP1 ITGB2
11	cellular response to UV-A	GO:0071492	9.56	MMP9 MMP1
12	collagen catabolic process	GO:0030574	9.56	MMP9 MMP26 MMP10 MMP1
13	inflammatory response	GO:0006954	9.5	TNF PSTPIP1 MEFV ITGB2 IL1R1 IFNA2
14	positive regulation of humoral immune response mediated by circulating immunoglobulin	GO:0002925	9.48	TNF NOD2
15	cellular extravasation	GO:0045123	9.43	TNF ITGB2
16	positive regulation of prostaglandin-E synthase activity	GO:2000363	9.32	NOD2 ITGB2
17	cytokine-mediated signaling pathway	GO:0019221	9.28	TNF MMP9 MMP1 ITGB2 IL1R1 IFNA2

Molecular functions related to Pyoderma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytokine activity	GO:0005125	9.46	TNF IFNA2 CXCL8 CSF3
2	metallopeptidase activity	GO:0008237	9.26	MMP9 MMP26 MMP10 MMP1
3	metalloendopeptidase activity	GO:0004222	8.92	MMP9 MMP26 MMP10 MMP1

Sources

Sources for Pyoderma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 05-Apr-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ Tocris

⁷⁰ UMLS

⁷¹ UMLS via Orphanet

⁷² UniProtKB/Swiss-Prot

⁷³ Wikipedia